GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, ...

GSK confirmed that the program is progressing to Phase 3 in ... In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac ...

Listing Sanofi and GlaxoSmithKline as firms that left the country due ... "The order targets healthcare products including pharmaceuticals, diagnostics, medical devices, biologicals and medical ...

Fitch Solutions has predicted that the naira would slide to as low as N1,993 per dollar in 2028, severely impacting Nigeria’s ...

GSK is delivering consistent financial performance ... I don't think we've given the peak penetration rate. But if you look at biological penetration, it is still disappointingly low.

This procedure uses Al algorithms to analyse large datasets, such as chemical libraries and biological interactions ...

Holcim has been named by the Science Based Targets Network (SBTN) as one of the first three companies globally to adopt ...

GSK is enlisting the aid of China’s Chongqing Zhifei Biological Products (Zhifei) to drive sales of its most important vaccine, Shingrix, in China over the next few years, and may also call upon ...

The continent is being drenched in an avalanche of medical disinformation with the aim of undermining western influence ...

[208] AS04 is another EU-registered adjuvant present in an HPV vaccine (Cervarix) as well as in a Hepatitis B vaccine (Fendrix® [GSK Biologicals]). For this adjuvant, no effect on any of the ...

This article highlights several inspiring men and women working across academia and industry who are breaking barriers and ...